@article{JTD2022,
author = {Kai-Xiong Liu and Bing Xu and Jie Wang and Jing Zhang and Hai-Bo Ding and Felinda Ariani and Jie-Ming Qu and Qi-Chang Lin},
title = {Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis},
journal = {Journal of Thoracic Disease},
volume = {6},
number = {3},
year = {2014},
keywords = {},
abstract = {Purpose: To evaluate the efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (AECOPD).
Methods: We searched PubMed, EMBASE, and the Web of Science for relevant studies. Two reviewers extracted data and reviewed the quality of the studies independently. The primary outcome was clinical success at early follow-up. Study-level data were pooled using a random-effects model when I2 was >50% or a fixed-effects model when I2 was <50%.
Results: Eleven randomized controlled studies were considered. There was no difference between moxifloxacin and comparator agents with regard to treatment success in intention-to-treat (ITT) [odds ratio (OR) =1.18, 95% confidence interval (CI) 0.98-1.42], clinically evaluable (CE) (OR 1.13, 95% CI, 0.93-1.37) patients, or adverse effects in general (OR 1.00, 95% CI, 0.86-1.17). Moxifloxacin was associated with better microbiological success (OR 1.45; 95% CI, 1.14-1.85).
Conclusions: Moxifloxacin was as clinically equivalent and bacteriologically superior to the antibiotic regimens routinely used in patients with AECB and AECOPD. Moxifloxacin therapy may be a promising and safe alternative to empirical treatment for AECB and AECOPD.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/2022}
}